Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06591819 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hypofractionated WPPT With HDR Boost

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 2026 to Jan 2034 Completion date: Dec 2031 to Dec 2035v4 Show 1 more changeShow less
    • Completion date: Dec 2031 to Dec 2035
  2. Start date: Oct 28, 2024 to Jan 15, 2025 Primary completion date: Oct 2026 to Jan 2026 · Completion date: Oct 2031 to Dec 2031v3 Show 2 more changesShow less
    • Primary completion date: Oct 2026 to Jan 2026
    • Completion date: Oct 2031 to Dec 2031
  3. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Sep 2026 to Oct 2026 · Completion date: Sep 2026 to Oct 2031 · Start date changed from estimate of Sep 9, 2024 to Oct 28, 2024 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Sep 2026 to Oct 2026
    • Completion date: Sep 2026 to Oct 2031
    • Start date changed from estimate of Sep 9, 2024 to Oct 28, 2024
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Trial Details
NCT Number NCT06591819
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Prostate Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov